Halozyme Therapeutics, Inc.  

(Public, NASDAQ:HALO)   Watch this stock  
Find more results for halo
10.55
-0.29 (-2.68%)
Apr 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.47 - 10.98
52 week 6.96 - 25.25
Open 10.79
Vol / Avg. 1.24M/1.73M
Mkt cap 1.31B
P/E     -
Div/yield     -
EPS -0.26
Shares 129.06M
Beta 2.00
Inst. own 78%
May 9, 2016
Q1 2016 Halozyme Therapeutics Inc Earnings Call - 4:30PM EDT - Add to calendar
May 9, 2016
Q1 2016 Halozyme Therapeutics Inc Earnings Release - 4:00PM EDT - Add to calendar
May 5, 2016
Halozyme Therapeutics Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
May 4, 2016
Halozyme Therapeutics Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
Apr 18, 2016
Halozyme Therapeutics Inc American Association Cancer Research Investor Corporate Call
Mar 15, 2016
Halozyme Therapeutics Inc at Barclays Global Healthcare Conference - Webcast
Mar 9, 2016
Halozyme Therapeutics Inc at Cowen Health Care Conference
Feb 29, 2016
Q4 2015 Halozyme Therapeutics Inc Earnings Call
Feb 29, 2016
Q4 2015 Halozyme Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 8.27% -23.86%
Operating margin 10.46% -20.33%
EBITD margin - -19.08%
Return on average assets 10.17% -18.54%
Return on average equity 46.31% -76.42%
Employees 216 -
CDP Score - -

Address

11388 Sorrento Valley Rd
SAN DIEGO, CA 92121-1345
United States - Map
+1-858-7948889 (Phone)
+1-858-7048311 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Company’s development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.

Officers and directors

Kathryn E. Falberg Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Helen I. Torley President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Laurie Stelzer Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Harry J. Leonhardt Esq. Senior Vice President, Chief Compliance Officer, General Counsel
Age: 56
Bio & Compensation  - Reuters
Athena Countouriotis M.D. Senior Vice President, Chief Medical Officer
Age: 44
Bio & Compensation  - Reuters
Jim Daly Director
Bio & Compensation  - Reuters
Jeffrey W. Henderson Director
Age: 49
Bio & Compensation  - Reuters
Jean-Pierre Bizzari M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Kenneth J. Kelley Independent Director
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Randal J. Kirk Independent Director
Age: 61
Bio & Compensation  - Reuters